Skip to main content

Table 1 Global patient characteristics and according to groups

From: Immunomodulatory treatment and surgical management of idiopathic uveitis and juvenile idiopathic arthritis-associated uveitis in children: a French survey practice

Characteristics Total
n = 76
Discontinuation group n = 5 Maintenance group
n = 71
Age at diagnosis — yr (mean ±SD) 4.4 ±2.7 4.1 ±2.2 4.5±2.7
Female — no. (%) 49 (64.5) 4 (80.0) 45 (63.4)
First manifestation — no. (%)
 Arthritis 38 (50.0) 2 (40.0) 36 (50.7)
 Uveitis 31 (40.8) 2 (40.0) 29 (40.8)
 Both 7 (9.2) 1 (20.0) 6 (8.5)
Uveitis — no. (%)
 JIA-associated uveitis 52 (68.4) 3 (60.0) 49 (69.0)
 Idiopathic uveitis 24 (31.6) 2 (40.0) 22 (31.0)
ANA positive — no./total no. (%)a 70/74 (94.6) 5 (100) 65/69 (94.2)
Type of uveitis — no. (%)
 Anterior 67 (88.2) 4 (80.0) 63 (88.7)
 Panuveitis 9 (11.8) 1 (20.0) 8 (11.3)
Age at surgery — yr (mean ±SD) 9.2 ±3.3 8.3±4.2 9.2±3.2
Surgery — no. (%)
 Cataract 32 (42.1) 4 (80.0) 28 (39.4)
 Posterior capsule opacification 12 (15.8) 1 (20.0) 11 (15.5)
 Glaucoma 23 (30.3) 0 (0.0) 23 (32.4)
 Needling 4 (5.3) 0 (0.0) 4 (5.6)
 Material removal 3 (3.9) 0 (0.0) 3 (4.2)
 Retinal detachment 2 (2.6) 0 (0.0) 2 (2.8)
Immunosuppressive therapies — no. (%)
 Methotrexate + Adalimumab 42 (55.3) 2 (40.0) 40 (56.3)
 Methotrexate 13 (17.1) 0 (0.0) 13 (18.3)
 Methotrexate + Infliximab 7 (9.2) 1 (20.0) 6 (8.5)
 Adalimumab 4 (5.3) 1 (20.0) 3 (4.2)
 Etanercept 4 (5.3) 0 (0.0) 4 (5.6)
 Infliximab 2 (2.6) 0 (0.0) 2 (2.8)
 Abatacept 1 (1.3) 1 (20.0) 0 (0.0)
 Mycophénolic acid 1 (1.3) 0 (0.0) 1 (1.4)
 Azathioprine + Adalimumab 1 (1.3) 0 (0.0) 1 (1.4)
 Methotrexate + Abatacept 1 (1.3) 0 (0.0) 1 (1.4)
Corticoid eye drops — no./total no. (%)a 46/72 (63.9) 3/5 (60.0) 43/67 (64.2)
Oral corticoid — no. (%) 31 (40.8) 2 (40.0) 29 (40.8)
Ophthalmic remission — no./total no. (%)a 65/70 (92.9) 5/5 (100) 60/65 (92.3)
Preoperative adjustement— no./total no. (%)a
 Corticosteroids pulse 21/74 (28.4) 2/5 (40.0) 19/69 (27.5)
 Increase oral corticosteroids 21/73 (28.8) 3/5 (60.0) 18/68 (26.5)
Peroperative adjustement — no./total no. (%)a
 Corticosteroids pulse 29/69 (42.0) 2/5 (40.0) 27/64 (42.2)
 Subconjunctival injection of corticosteroids 39/62 (62.9) 4/5 (80.0) 35/57 (61.4)
 Intracamerular corticosteroids 11/61 (18.0) 0/5 (0.0) 11/56 (19.6)
 Intracamerular antibiotics 27/60 (45.0) 3/5 (60.0) 24/55 (43.6)
 Antibiotics eyedrops 51/60 (85.0) 2/5 (40.0) 49/55 (89.1)
 Local antineoplastic drugs 16/65 (24.6) 0/5 (0.0) 16/60 (26.7)
Postoperative adjustement — no./total no. (%)a
 Corticosteroids pulse 18/72 (25.0) 2/5 (40.0) 16/67 (23.9)
 Increase oral corticosteroids 60/74 (81.1) 5/5 (100) 55/69 (79.7)
 Corticosteroids eyedrops 61/62 (98.4) 4/5 (80.0) 57/57 (100)
 Antibiotics eyedrops 59/59 (100) 5/5 (100) 54/54 (100)
  1. aData not available for some patients